This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. market for pain management products. Product areas covered by the scope of this report include pain management pharmaceuticals (e.g., nonprescription analgesics and anesthetics including systemic and topical formulations, as well as prescription analgesics and anesthetics including prescription NSAIDs, opioid analgesics, opioid/nonopioid combination analgesics, antimigraine analgesics, adjuvant analgesics, and general/regional/local anesthetics) and pain management devices (e.g., electrical stimulators including TENS systems and neurostimulators, as well as analgesia infusion pumps including implantable and external models).
During the forecast period covered by this report, the combined U.S. market for pain management products is projected to increase from $36.4 billion in 2013 to $44.7 billion in the year 2018. Pain management pharmaceuticals account for more than 92% of total sales, with pain management devices accounting for the remaining 8% of sales.
EXECUTIVE SUMMARY i. Pain Management Pharmaceuticals a. Nonprescription Analgesics and Anesthetics i. Nonprescription Systemic Analgesics ii. Nonprescription Topical Analgesics iii. Market Forecast b. Prescription Analgesics and Anesthetics i. Prescription Non-Steroidal Anti-Inflammatory Drugs ii. Opioid Analgesics iii. Opioid/Nonopioid Combination Analgesics iv. Antimigraine Analgesics v. Adjuvant Analgesics vi. General, Regional, and Local Anesthetics vii. Market Forecast c. Combined Market Forecast ii. Pain Management Devices a. Electrical Stimulators i. Transcutaneous Electrical Nerve Stimulators ii. Neurostimulators iii. Market Forecast b. Analgesia Infusion Pumps i. Implantable Analgesia Infusion Pumps ii. External Analgesia Infusion Pumps iii. Market Forecast c. Combined Market Forecast iii. Combined Market Forecast Exhibit ES-1: Nonprescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-2: Prescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-3: Pain Management Pharmaceuticals, Combined Market Share, by Product Segment, 2013 and 2018 Exhibit ES-4: Electrical Stimulators, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-5: Analgesia Infusion Pumps, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-6: Pain Management Devices, Combined Market Share, by Product Segment, 2013 and 2018 Exhibit ES-7: Pain Management Pharmaceuticals and Devices, Combined Market Share, by Product Segment, 2013 and 2018 1. PAIN MANAGEMENT OVERVIEW 1.1 Pain Physiology 1.1.1 The Nervous System 1.1.2 Pain Perception 1.1.3 Pain Classification 18.104.22.168 Nociceptive Pain 22.214.171.124 Non-Nociceptive Pain 126.96.36.199 Acute Pain 188.8.131.52 Chronic Pain 1.2 Pain Assessment Techniques 1.3 Pain Prevalence 1.4 Common Pain Syndromes 1.4.1 Arthritis Pain 1.4.2 Back Pain 1.4.3 Burn Pain 1.4.4 Cancer Pain 1.4.5 Headache Pain 1.4.6 Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Pain 1.4.7 Obstetric Pain 1.4.8 Podiatric Pain 1.4.9 Sciatic Pain 1.4.10 Temporomandibular Pain 1.4.11 Trauma Pain 1.5 Clinical Approaches to Pain Management 1.5.1 Pain Management Guidelines 1.5.2 Pain Management Guidelines for Older Adults 1.5.3 Interventional Pain Management Guidelines 1.5.4 Pain Management Options 184.108.40.206 Pharmaceutical Options 220.127.116.11 Device-Based Options 18.104.22.168 Alternative Therapy Options Exhibit 1-1: Common Causes of Neuropathic Pain Exhibit 1-2: United States Population, by Selected Ages, 1990-2050 Exhibit 1-3: Overview of the Joint Commission's Standards for Pain Assessment and Management 2. PAIN MANAGEMENT PHARMACEUTICALS 2.1 Pharmaceutical Formulations and Drug Delivery 2.1.1 Oral Drug Delivery 2.1.2 Injection/Infusion Drug Delivery 22.214.171.124 Injection 126.96.36.199.1 Intramuscular Injection 188.8.131.52.2 Subcutaneous Injection 184.108.40.206 Infusion 220.127.116.11.1 Intravenous Infusion 18.104.22.168.2 Intraspinal Infusion 22.214.171.124.3 Intraoperative Site Infusion 2.1.3 Inhalation Drug Delivery 2.1.4 Transdermal Drug Delivery 2.1.5 Transmucosal Drug Delivery 2.1.6 Nonsteroidal Anti-Inflammatory Drugs 126.96.36.199 Heart Attack and Hypertension Risks 188.8.131.52 The Food and Drug Administration and Labeling 184.108.40.206 Naproxen Risks 2.2 The Benefits of Aspirin 2.2.1 Aspirin and Heart Attack/Stroke Prevention 2.2.2 Aspirin and Heart Failure 2.2.3 Aspirin and Cancer Prevention 2.3 Market Analysis 2.3.1 Nonprescription Analgesics and Anesthetics 220.127.116.11 Market Forecast 18.104.22.168 Nonprescription Systemic Analgesics 22.214.171.124.1 Acetaminophen 126.96.36.199.2 Nonprescription Nonsteroidal Anti-Inflammatory Drugs 188.8.131.52.3 Market Forecast 184.108.40.206.4 Competitive Analysis 220.127.116.11 Nonprescription Topical Analgesics and Anesthetics 18.104.22.168.1 Amino Amides and Esters 22.214.171.124.2 Capsaicin 126.96.36.199.3 Methyl and Trolamine Salicylates 188.8.131.52.4 Topical Patches 184.108.40.206.5 Market Forecast 220.127.116.11.6 Competitive Analysis 2.3.2 Prescription Analgesics and Anesthetics 18.104.22.168 Market Forecast 22.214.171.124 Prescription Nonsteroidal Anti-Inflammatory Drugs 126.96.36.199.1 Acetic Acid Derivatives 188.8.131.52.2 Anthranilic Acid Derivatives 184.108.40.206.3 Cyclooxygenase-2 Selective Inhibitors 220.127.116.11.4 Enolic Acid Derivatives 18.104.22.168.5 Propionic Acid Derivatives 22.214.171.124.6 Salicylic Acid Derivatives 126.96.36.199.7 Market Forecast 188.8.131.52.8 Competitive Analysis 184.108.40.206 Opioid Analgesics 220.127.116.11.1 Buprenorphine 18.104.22.168.2 Butorphanol 22.214.171.124.3 Codeine 126.96.36.199.4 Fentanyl 188.8.131.52.5 Hydromorphone 184.108.40.206.6 Levorphanol 220.127.116.11.7 Meperidine 18.104.22.168.8 Morphine 22.214.171.124.9 Nalbuphine 126.96.36.199.10 Oxycodone 188.8.131.52.11 Oxymorphone 184.108.40.206.12 Pentazocine 220.127.116.11.13 Propoxyphene 18.104.22.168.14 Remifentanil 22.214.171.124.15 Tramadol 126.96.36.199.16 Tapentadol 188.8.131.52.17 Hydrocodone 184.108.40.206.18 Market Forecast 220.127.116.11.19 Competitive Analysis 18.104.22.168 Opioid/Nonopioid Combination Analgesics 22.214.171.124.1 Market Forecast 126.96.36.199.2 Competitive Analysis 188.8.131.52 Antimigraine Analgesics 184.108.40.206.1 Diclofenac 220.127.116.11.2 Dihydroergotamine 18.104.22.168.3 Divalproex Sodium 22.214.171.124.4 Triptans 126.96.36.199.5 Market Forecast 188.8.131.52.6 Competitive Analysis 184.108.40.206 Adjuvant Analgesics 220.127.116.11.1 Anticonvulsants 18.104.22.168.2 Antidepressants 22.214.171.124.3 Corticosteriods 126.96.36.199.4 Market Forecast 188.8.131.52.5 Competitive Analysis 184.108.40.206 General, Regional, and Local Anesthetics 220.127.116.11.1 Inhalation General Anesthetics 18.104.22.168.2 Intravenous General Anesthetics 22.214.171.124.3 Anesthetics Used in Balanced Anesthesia 126.96.36.199.4 Regional/Local Anesthetics 188.8.131.52.5 Market Forecast 184.108.40.206.6 Competitive Analysis 2.3.3 Combined Market Forecast Exhibit 2-1: Advantages and Disadvantages of Common Drug Delivery Methods Exhibit 2-2: 2014, Selected Nonprescription Analgesics and Anesthetics Exhibit 2-3: 2014, Selected Prescription Analgesics and Anesthetics Exhibit 2-4: Nonprescription Analgesics and Anesthetics, Market Forecast 2013-2018 Exhibit 2-5: Nonprescription Systemic Analgesics, Market Forecast, 2013-2018 Exhibit 2-6: 2013, Nonprescription Systemic Analgesics Market, Share by Supplier Exhibit 2-7: Nonprescription Topical Analgesics/Anesthetics, Market Forecast, 2013-2018 Exhibit 2-8: 2013, Nonprescription Topical Analgesics/Anesthetics Market, Share by Supplier Exhibit 2-9: Prescription Analgesics and Anesthetics, Market Forecast, 2013-2018 Exhibit 2-10: Prescription Nonsteroidal Anti-Inflammatory Drugs, Market Forecast, 2013-2018 Exhibit 2-11: 2013, Prescription Nonsteroidal Anti-Inflammatory Drugs Market, Share by Supplier Exhibit 2-12: Prescription Opioid Analgesics, Market Forecast, 2013-2018 Exhibit 2-13: 2013, Prescription Opioid Analgesics Market, Share by Supplier Exhibit 2-14: Prescription Opioid/Nonopioid Combination Analgesics, Market Forecast, 2013-2018 Exhibit 2-15: Prescription Antimigraine Analgesics, Market Forecast, 2013-2018 Exhibit 2-16: 2013, Prescription Antimigraine Analgesics Market, Share by Supplier Exhibit 2-17: Prescription Adjuvant Analgesics, Market Forecast, 2013-2018 Exhibit 2-18: 2013, Prescription Adjuvant Analgesics Market, Share by Supplier Exhibit 2-19: General, Regional, and Local Anesthetics, Market Forecast, 2013-2018 Exhibit 2-20: 2013, General, Regional, and Local Anesthetics Market, Share by Supplier Exhibit 2-21: Pain Management Pharmaceuticals, Combined Market Forecast, 2013-2018 3. PAIN MANAGEMENT DEVICES 3.1 Electrical Stimulators 3.1.1 Transcutaneous Electrical Nerve Stimulators 220.127.116.11 Market Forecast 18.104.22.168 Competitive Analysis 3.1.2 Neurostimulators 22.214.171.124 Occipital Nerve Stimulation 126.96.36.199 Neuromuscular Stimulators 188.8.131.52 Spinal Cord and Peripheral Nerve Stimulators 184.108.40.206 Market Forecast 220.127.116.11 Competitive Analysis 3.2 Analgesia Infusion Pumps 3.2.1 Implantable Analgesia Infusion Pumps 18.104.22.168 Market Forecast 22.214.171.124 Competitive Analysis 3.2.2 External Analgesia Infusion Pumps 126.96.36.199 Nerve Block 188.8.131.52 Patient-Controlled Analgesia Infusion Pumps 184.108.40.206 Products 220.127.116.11 Market Forecast 18.104.22.168 Competitive Analysis 3.3 Combined Market Forecast Exhibit 3-1: Proposed Fourth Step of the World Health Organization Analgesic Ladder Exhibit 3-2: Selected Painful Conditions Appropriate for Electrical Stimulation Therapy Exhibit 3-3: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2013-2018 Exhibit 3-4: 2013, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier Exhibit 3-5: Neurostimulators, Market Forecast, 2013-2018 Exhibit 3-6: 2013, Spinal Cord Stimulators Market, Share by Supplier Exhibit 3-7: 2013, Neuromuscular Stimulators Market, Share by Supplier Exhibit 3-8: Implantable Analgesia Infusion Pumps, Market Forecast, 2013-2018 Exhibit 3-9: 2013, Implantable Analgesia Infusion Pumps Market, Share by Supplier Exhibit 3-10: External Analgesia Infusion Pumps, Market Forecast, 2013-2018 Exhibit 3-11: 2013, External Analgesia Infusion Pumps Market, Share by Supplier Exhibit 3-12: Pain Management Devices, Combined Market Forecast, 2013-2018 4. COMPANY PROFILES 4.1 AstraZeneca PLC 4.2 Baxter Healthcare, Inc./Baxter International, Inc. 4.3 Bayer HealthCare AG/Bayer AG 4.4 Boston Scientific Corporation 4.5 CareFusion Corporation 4.6 Chattem, Inc./sanofi-aventis LLC 4.7 DJO Global, Inc. 4.8 Eli Lilly and Company 4.9 Endo Pharmaceutical Holdings, Inc./Endo International PLC 4.10 GlaxoSmithKline PLC 4.11 Hospira, Inc. 4.12 International Rehabilitative Sciences, Inc., d/b/a RS Medical 4.13 Johnson & Johnson 4.14 Medtronic, Inc. 4.15 Pfizer, Inc. 4.16 Purdue Pharma LP 4.17 Teva Pharmaceutical Industries LTD APPENDIX: COMPANY LISTING